ライフサイエンスコーパス: mutein

1 bited equally by either TNF(p60) or TNF(p80) mutein.

2 d by TNF and by p60 or p80 receptor-specific muteins.

3 major conformational changes in any of these muteins.

4 Treatment of these cells with TNF(p60) mutein activate NF-kappa B within 30 min, whereas TNF(p8

5 ities of chimeric interspecies and homologue muteins and epitope mapping of a monoclonal antibody (Mo

6 We have exploited receptor-selective muteins and evaluated phosphorylation of receptor-specif

7 Thus, the human IL-15 superagonist muteins and fusions may create opportunities to construc

8 l model, predict that the properties of IL-2 mutein are a consequence of the reduction, of at least t

9 In contrast, the D9N and K37A muteins are 7-12-fold less active that wild-type ApB, an

10 The secondary structures of both these muteins are identical to that of the wild-type toxin as

11 napse composed of membrane-tethered cytokine muteins bound to cell-surface cytokine receptors on tumo

12 ular variant of interleukin-6 (interleukin-6 mutein) but not with hepatocyte growth factor or lisofyl

13 In organ culture, a TNFR1-specific mutein changes phosphorylation of ASK1 to threonine 845,

14 increase in biological activity of the IL-15 mutein compared with the native molecule based on prolif

15 One of these muteins, containing the mutation Arg-121 to Glu (IL-4/R1

16 This HVEM mutein did not bind CD160 or TNF ligands but did bind BT

17 A TNFR2-specific mutein down-regulates TNFR1 in glomerular EC, up-regulat

18 The TB muteins, E706A and Q683A, have less pronounced deviation

19 e NF-kappa B within 30 min, whereas TNF(p80) mutein, even at a 1000-fold excess, had no effect, sugge

20 The IL-15N72D mutein exhibited superagonist activity through improved

21 All muteins exhibited reduced polymerase activity on both RN

22 prototype zetakine incorporates an IL13 E13Y mutein for selective binding to IL13Ralpha2.

23 re also obtained for the charge neutralizing muteins for Lys-29 and Lys-33 in the loop region.

24 inding studies were conducted on human IL-15 muteins generated by site-directed mutagenesis.

25 sults in a product that fails to fold, while muteins H39A and H34A have activities very similar or id

26 ions, two survival-selective recombinant NGF muteins, i.e./7-84-103 and KKE/7-84-103, were generated.

27 tic excimer emission bands of pyrene-labeled muteins indicated stacking of the two pyrene rings in th

28 sis whereas wild-type TNF and TNFR2-specific mutein induce tubular cells to express proliferating cel

29 The p80 mutein, like TNF and the p60 mutein, induced apoptosis and activation of NF-kappa B a

30 However, the R25K mutein is almost as active as natural toxin.

31 The p80 mutein, like TNF and the p60 mutein, induced apoptosis a

32 liary neurotrophic factor (CNTF), Axokine (a mutein of CNTF), leukemia inhibitory factor, basic fibro

33 opagate CAR(+) T cells, we developed a novel mutein of IL-21 bound to the cell surface of aAPC that r

34 For comparison, D732A mutein of pol I was also included.

35 The E13Y amino acid substitution of the IL13 mutein of the zetakine endows CTL transfectants with the

36 Recombinant muteins of IL13 were produced in Escherichia coli, and t

37 at neither the wild type nor any of the K152 muteins of MuLV RT are capable of forming stable ternary

38 Furthermore, this mutein prolonged survival in a model of graft-versus-hos

39 e effects of shIL-4Ralpha and an IL-4 double mutein (R121D/Y124D, IL-4R antagonist) on IL-4- and IL-1

40 Both muteins reduced neuritogenesis in PC12 (TrkA(+)/p75(NTR+

41 The muteins representing conserved aspartate (Asp-707 of TB

42 issue treated with wild-type TNF or specific muteins selective for TNFR1 (R1-TNF) or TNFR2 (R2-TNF).

43 By using TNF muteins specific to the p60 and p80 receptors, we have p

44 The C197S-mutein still forms a tetrameric structure but shows impa

45 P resistance patterns were unchanged for all muteins, suggesting no participation of K152 in ddNTP re

46 tudy was aimed at developing recombinant NGF muteins that did not support neuritogenesis while mainta

47 est a new option for HIV gene therapy; bcl-2 muteins that have noncleavable alterations surrounding t

48 ration of survival-selective recombinant NGF muteins that may represent novel pharmacologic lead agen

49 However, two SLPI mutants (or muteins) that contain single amino acid substitutions an

50 inding scFv and an IL13Ralpha2-binding IL-13 mutein to make a tandem CAR exodomain (TanCAR) and a CD2

51 The binding kinetics of these muteins to 11 monoclonal, inhibitory anti-FVIII-C2 antib

52 The ability of individual muteins to add dNTP on the covalently cross-linked enzym

53 Wild-type TNF and TNFR1-specific mutein trigger tubular cell apoptosis whereas wild-type

54 F-mediated activation of NF-kappa B TNF(p60) mutein was also effective in cell killing, but the TNF(p

55 This mutein was found to retain substantial IL-5 receptor alp

56 effective in cell killing, but the TNF(p80) mutein was totally ineffective.

57 These muteins were evaluated in T cell and endothelial cell as

58 A series of IL-4 muteins were generated that were substituted in the regi

59 eted mutagenesis of human IL-2 to generate a mutein with approximately 3,000-fold in vitro selectivit

60 nt of its antiprotease activity because SLPI muteins, with significantly lower antiprotease activity,